Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors

1. A method of treating a disease or disorder associated with modulation of USP7 comprising, administering to a patient in need thereof an effective amount of a compound of formula (Ib):

or a pharmaceutically acceptable salt thereof,

wherein:

X 1 is C;

R 2 is (C 1 -C 8 ) alkyl, (C 6 -C 14 ) aryl, heteroaryl, (C 5 -C 8 ) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R 8 ;

R 4 is H or (C 1 -C 6 ) alkyl;

R 6 is H;

R 7 is H, halogen, —NR 17 C(O)R 18 or —NR 17 C(O)NR 18 R 19 ;

each R 8 is independently (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, CN, —(C 0 -C 4 )-alkylene-aryl, —(C 0 -C 4 )-alkylene-heteroaryl, (C 3 -C 10 ) cycloalkyl, heterocycloalkyl, —C(O)R 12 , —S(O) q R 12 , —(C 0 -C 3 )-alkylene-NR 12 R 13 , or —OR 12 , wherein alkyl, alkylene, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R 9 ;

each R 9 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, halogen, CN, —S(O) q R 14 , —S(O) q NR 14 R 15 , —C(O)NR 14 R 15 , —NR 14 C(O)R 15 , (C 6 -C 14 ) aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, or heterocycloalkyl, wherein alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R 10 ; or

two R 9 together with the atoms to which they are attached form a (C 6 -C 14 ) aryl ring optionally substituted with one or more R 10 ; or

two R 9 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 10 ; or

two R 9 together with the atoms to which they are attached form a (C 5 -C 8 ) cycloalkyl ring optionally substituted with one or more R 10 ; or

two R 9 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 10 ;

each R 10 is independently at each occurrence (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, —OH, or CN; or

two R 10 together with the atoms to which they are attached form a (C 6 -C 14 ) aryl ring optionally substituted with one or more R 11 ; or

two R 10 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 11 ; or

two R 10 together with the atoms to which they are attached form a (C 5 -C 8 ) cycloalkyl ring optionally substituted with one or more R 11 ; or

two R 10 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 11 ;

each R 11 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, —NH 2 , or CN;

each R 12 and R 13 is independently H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 6 -C 14 ) aryl, heteroaryl, (C 5 -C 8 ) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R 16 ;

each R 14 and R 15 is independently H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 6 -C 14 ) aryl, heteroaryl, (C 5 -C 8 ) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R 16 ; or

R 14 and R 15 together with the nitrogen to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 16 , when R 9 is —C(O)NR 14 R 15 ;

each R 16 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, or CN;

R 17 is independently H or (C 1 -C 6 ) alkyl;

R 18 is independently (C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, heteroaryl, (C 5 -C 8 ) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R 20 ;

R 19 is independently H or (C 1 -C 6 ) alkyl;

each R 20 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, CN, (C 6 -C 14 ) aryl, —O(C 6 -C 14 ) aryl, or heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more R 21 ; or

two R 20 together with the atoms to which they are attached form a (C 6 -C 14 ) aryl ring optionally substituted with one or more R 21 ; or

two R 20 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 21 ; or

two R 20 together with the atoms to which they are attached form a (C 5 -C 8 ) cycloalkyl ring optionally substituted with one or more R 21 ; or

two R 20 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 21 ;

each R 21 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, or CN; and

q is independently at each occurrence 0, 1, or 2.

2. The method according to claim 1 , wherein R 4 is H.

3. The method according to claim 2 , wherein R 7 is H.

4. The method according to claim 3 , wherein R 2 is (C 1 -C 8 ) alkyl, wherein the alkyl is optionally substituted with one more R 8 .

5. The method according to claim 4 , wherein R 2 is (C 1 -C 8 ) alkyl, wherein the alkyl is substituted with one more R 8 .

6. The method according to claim 5 , wherein R 2 is (C 1 -C 8 ) alkyl, wherein the alkyl is substituted with —(C 0 -C 4 )-alkylene-aryl.

7. The method according to claim 5 , wherein R 2 is (C 1 -C 8 ) alkyl, wherein the alkyl is substituted with —(C 0 -C 4 )-alkylene-heteroaryl.

8. The method according to claim 1 , wherein the compound is (R)-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one, or a pharmaceutically acceptable salt thereof.

9. The method according to claim 1 , wherein the compound is 3-((1-(3-(1H-pyrrol-1-yl)butanoyl)-4-hydroxypiperidin-4-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one, or a pharmaceutically acceptable salt thereof.

10. The method according to claim 1 , wherein the disease or disorder associated with modulation of USP7 is cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases.